Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) today announces its results for the half year to 30 June 2011.

Highlights

Half year financial highlights

  • Net sales increased by 22.7% to Bangladesh Taka ("BDT") 3,642.3m / £30.5m (2010: BDT 2,968.7 m / £27.3m)
    • Domestic sales increased 22.8% to BDT 3,468.8m / £29.1m (H1 2010: BDT 2,825.9m / £26.0m)
    • Export sales increased 21.6% to BDT 173.5m / £1.5m (H1 2010: BDT 142.7m / £1.3m)
  • Profit before tax increased by 9.6% to BDT 764.5m / £6.4m (H1 2010: BDT 697.3m / £6.4m)
  • EPS increased by 7.9% to BDT 2.72 / 2.3 pence (2010: BDT 2.52 / 2.3 pence)

Second quarter highlights

  • Net sales increased by 20% to BDT 1,970.6m / £16.5m (2010: BDT1,642.0m / £15.1m)
  • Profit before tax increased by 21.6% to BDT 461.4m / £3.9m (2010: BDT 379.3m / £3.5m)

Operational highlights

  • 10 new products registered in overseas markets
  • Launched 21 new products across different therapeutic classes
  • Plant and Machinery for the New MDI (Metered Dose Inhaler) facility installed and commissioned, trial production scheduled August 2011

Post-period events

  • Received GMP (Good Manufacturing Practices) accreditation from Austrian regulatory authority for Oral Solid and Sterile Eye Drop Facilities
    • Approval recognized throughout European Union (EU)

This is for information of the valued Shareholders of the Company that the Board of Directors in their meeting held on 28 April, 2011 at 3.30 p.m. has decided in regard to 35th Annual General Meeting (AGM) of the Shareholders of the Company for the year ended 31st December, 2010 as follows:

pdf Press Releases 28 April 2011

We are pleased to present the un-audited Financial Statements of Beximco Pharmaceuticals Ltd. for the first quarter ended March 31, 2011 as per Securities and Exchange Commission Notification No. SEC/CMRRCD/2008-183/Admin/03-34 dated September 27, 2009.

pdf Open/ Download

This is for information of the valued Shareholders of the Company that the Board of Directors in their meeting held on 29 April, 2010 at 3.30 p.m. has decided in regard to 34th Annual General Meeting (AGM) of the Shareholders of the Company for the year ended 31st December, 2009 the followings:

pdf Press Releases 29 April 2010

This is for information of all concerned that the Board of Directors of Beximco Pharmaceuticals Ltd in its meeting held on 2 September 2009 at 5:00 PM reviewed the situation arising out of the imposition of lock-in on shares and warrants issuable to GEM Global Yield Fund Limited and subsequent non-receipt of fund from them. In view of this, the Board in its aforesaid meeting has decided to issue up to 4,100,000 Fully Convertible, 5% Dividend, Preference Shares of Taka 1,000 each on the following terms and conditions subject to approval of the shareholders of the Company in their Extra-Ordinary General Meeting (EGM) to be held on 15 October 2009 (with Record Date on 17 September 2009) at 11:00 AM at BEXIMCO Industrial Park, Sarabo, Kashimpur, Gazipur and SEC’s consent to the aforesaid Preference Share Issue...

pdf Press Releases 2 September 2009

We have audited the accompanying Balance Sheet of the Beximco Pharmaceuticals Limited as of December 31, 2008 and the related Profit and Loss Account, Statement of Changes in Equity and Statement of Cash Flows for the year then ended. These financial statements are the responsibility of the company’s management. Our responsibility is to express an opinion on these financial statements based on our audit...

pdf Press Releases 30 April 2008